Larimar Therapeutics (LRMR) PEG Ratio
Market Cap: $149.19M
Avg Volume: 808.94K
Industry: Biotechnology
Sector: Healthcare
PEG Ratio Summary
- Larimar Therapeutics's trailing twelve month (TTM) PEG ratio is 0.12.
- Larimar Therapeutics's annual PEG ratio as of today is -0.05.
- Larimar Therapeutics's quarterly PEG ratio is -0.02.
What is the PEG Ratio?
The PEG ratio (Price/Earnings to Growth ratio) is a valuation metric for determining the relative trade-off between the price of a stock, the earnings generated per share (EPS), and the company's expected growth. A lower PEG ratio suggests that a stock may be undervalued given its earnings performance and growth potential.
How is the PEG Ratio calculated?
The PEG ratio is calculated by dividing the P/E ratio by the annual EPS growth. The formula is:
PEG Ratio = (P/E Ratio) / (EPS Growth Rate)
This helps investors to determine a stock's value while considering the company's earnings growth.
Related Metrics
Other important metrics to assess Larimar Therapeutics's financial health include:
- P/E Ratio (Price to Earnings Ratio) - measures the company's current share price relative to its per-share earnings:
- Annual: -2.94
- Quarterly: -2.06
- TTM: -1.77
- P/S Ratio (Price to Sales Ratio) - compares the company's stock price to its revenues:
- Annual: 0.00
- Quarterly: 0.00
- TTM: 0.00
- P/B Ratio (Price to Book Ratio) - compares the company's market value to its book value:
- Annual: 1.38
- Quarterly: 1.38
- TTM: 0.83
- P/CF Ratio (Price to Cash Flow Ratio) - compares the company's market value to its cash flow:
- Annual: -3.35
- Quarterly: -10.87
- TTM: -2.02
These metrics provide insights into Larimar Therapeutics's financial health and its ability to meet short-term obligations. Comparing these ratios with industry benchmarks can offer a deeper understanding of the company's performance.
TTM PEG Ratio
0.12
Annual PEG Ratio
-0.05
Quarterly PEG Ratio
-0.02
Larimar Therapeutics Historical PEG Ratio
Historical P/E Ratio
Historical P/S Ratio
Historical P/B Ratio
Historical P/CF Ratio
Larimar Therapeutics Historical Financial Metrics
The table below shows various financial metrics for each year, with the latest data available for the last fiscal year 2024.
| Year | PEG Ratio | P/E Ratio | P/S Ratio | P/B Ratio | P/CF Ratio |
|---|---|---|---|---|---|
| 2024 | -0.05 | -2.94 | 0.00 | 1.38 | -3.35 |
| 2023 | 0.15 | -5.41 | 0.00 | 2.44 | -5.97 |
| 2022 | 0.06 | -3.11 | 0.00 | 0.96 | -3.86 |
| 2021 | 0.21 | -3.68 | 0.00 | 2.88 | -4.40 |
| 2020 | -0.14 | -6.01 | 0.00 | 2.84 | -6.03 |
| 2019 | 0.06 | -5.31 | 0.00 | -176.84 | -5.41 |
| 2018 | -6.57 | -2.60 | 0.00 | 1.71 | -3.10 |
| 2017 | 0.23 | -2.44 | 0.00 | 1.62 | -2.89 |
| 2016 | 0.06 | -1.50 | 0.00 | 0.71 | -1.67 |
| 2015 | -0.02 | -2.27 | 0.00 | 1.00 | -2.83 |
| 2014 | -0.19 | -24.45 | 0.00 | 8.56 | -31.66 |
| 2013 | -16.82 | -36.80 | 0.00 | 14.65 | -34.40 |
| 2012 | -6.84 | -37.19 | 0.00 | 64.07 | -37.98 |
| 2011 | 0.00 | -39.23 | 0.00 | 0.00 | -42.05 |
Related Metrics
Explore detailed financial metrics and analysis for LRMR.